<DOC>
	<DOC>NCT02636907</DOC>
	<brief_summary>This is an open-label, phase II study of BI 695501 to assess handling experience of patients with Rheumatoid Arthritis using an autoinjector. The extension phase is to provide patients with additional exposure to BI 695501 and to enhance the safety database for this compound.</brief_summary>
	<brief_title>Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Inclusion criteria: Moderately to severely active RA for at least 6 months, which is not adequately controlled by nonbiologics DMARDs. No contraindications to antiTNF agents. Either biologics naive or biologicsexperienced but with no experience of selfadministration medication using autoinjector or pen. Patients must be able and willing to selfinject BI 695501. Further inclusion criteria apply. Exclusion criteria: Experience with selfadministration of medication using an autoinjector or pen. American College of Rheumatology functional Class IV or wheelchair/ bed bound. Primary or secondary immunodeficiency. History of TB. Further exclusion criteria apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>